In conclusion, our results indicate that CAPE exhibits strong anti-inflammatory and immunomodulatory effects by suppressing NF-κB activation and T cell activity in EAE, implying the possibility of using CAPE as an immunomodulatory agent for MS treatment. The gene discussed is NFKB1; the disease is myeloid sarcoma.